These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 7107369

  • 1. The pharmacokinetics in mice and dogs of nitroimidazole radiosensitizers and chemosensitizers more lipophilic than misonidazole.
    White R, Workman P, Owen L.
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):473-6. PubMed ID: 7107369
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of hypoxic cell radiosensitizers: a review.
    Workman P.
    Cancer Clin Trials; 1980; 3(3):237-51. PubMed ID: 7438321
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.
    Akel G, Canal P, Mockey E, Vandevoorde E, Laurent F, Soula G.
    J Pharmacol; 1983; 14(1):67-77. PubMed ID: 6834852
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.
    Brown JM, Yu NY, Workman P.
    Br J Cancer; 1979 Mar; 39(3):310-20. PubMed ID: 465300
    [Abstract] [Full Text] [Related]

  • 5. Preclinical pharmacokinetics of benznidazole.
    Workman P, White RA, Walton MI, Owen LN, Twentyman PR.
    Br J Cancer; 1984 Sep; 50(3):291-303. PubMed ID: 6466543
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.
    White RA, Workman P.
    Br J Cancer; 1980 Feb; 41(2):268-76. PubMed ID: 7370166
    [Abstract] [Full Text] [Related]

  • 7. Structure-pharmacokinetic relationships for misonidazole analogues in mice.
    Workman P, Brown JM.
    Cancer Chemother Pharmacol; 1981 Feb; 6(1):39-49. PubMed ID: 7273265
    [Abstract] [Full Text] [Related]

  • 8. The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid.
    Dische S, Saunders MI, Riley PJ, Hauck J, Bennett MH, Stratford MR, Minchinton AI.
    Br J Cancer; 1981 Mar; 43(3):344-9. PubMed ID: 7225285
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and toxicology of continuously infused nitroimidazoles.
    Eifel PJ, Brown JM.
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1311-4. PubMed ID: 6236186
    [Abstract] [Full Text] [Related]

  • 10. A comparison of tumor and normal tissue levels of acidic, basic and neutral 2-nitroimidazole radiosensitizers in mice.
    Minchinton AI, Stratford MR.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1117-20. PubMed ID: 2943710
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans.
    Gianni L, Jenkins JF, Greene RF, Lichter AS, Myers CE, Collins JM.
    Cancer Res; 1983 Feb; 43(2):913-6. PubMed ID: 6848201
    [Abstract] [Full Text] [Related]

  • 12. A drug for improved radiosensitization in radiotherapy.
    Dische S, Fowler JF, Saunders MI, Stratford MR, Anderson P, Minchinton AI, Lee ME.
    Br J Cancer; 1980 Jul; 42(1):153-5. PubMed ID: 7426325
    [No Abstract] [Full Text] [Related]

  • 13. Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU.
    Workman P, Twentyman PR.
    Br J Cancer; 1982 Aug; 46(2):249-59. PubMed ID: 7150475
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole.
    Flockhart IR, Large P, Troup D, Malcolm SL, Marten TR.
    Xenobiotica; 1978 Feb; 8(2):97-105. PubMed ID: 415443
    [Abstract] [Full Text] [Related]

  • 15. Desmethylmisonidazole (Ro 05-9963): clinical pharmacokinetics after multiple oral administration.
    Stratford MR, Minchinton AI, Dische S, Saunders MI, Anderson P.
    Int J Radiat Oncol Biol Phys; 1982 Feb; 8(3-4):377-9. PubMed ID: 7107355
    [Abstract] [Full Text] [Related]

  • 16. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
    White RA, Workman P, Brown JM.
    Radiat Res; 1980 Dec; 84(3):542-61. PubMed ID: 6450431
    [No Abstract] [Full Text] [Related]

  • 17. Radiosensitizing, toxicological, and pharmacokinetic properties of hydroxamate analogues of nitroimidazoles as bifunctional radiosensitizers/chemical modifiers.
    Nagasawa H, Bando M, Hori H, Satoh T, Tada T, Onoyama Y, Inayama S.
    Int J Radiat Oncol Biol Phys; 1992 Dec; 22(3):561-4. PubMed ID: 1735696
    [Abstract] [Full Text] [Related]

  • 18. Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.
    Lee FY, Workman P.
    Cancer Chemother Pharmacol; 1986 Dec; 17(1):30-7. PubMed ID: 3698174
    [Abstract] [Full Text] [Related]

  • 19. Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.
    Workman P.
    Br J Cancer; 1979 Sep; 40(3):335-53. PubMed ID: 508562
    [Abstract] [Full Text] [Related]

  • 20. Clinical trials of radiosensitizers: what should we expect?
    Brown JM.
    Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):425-9. PubMed ID: 6231272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.